Woodline Partners LP Infla Rx N.V. Transaction History

Woodline Partners LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.18 - $1.74 $204,831 - $302,039	173,586 New	173,586 $302,000
Q3 2023 Nov 14, 2023	SELL	$2.66 - $4.33 $963,725 - $1.57 Million	-362,303 Reduced 73.55%	130,293 $388,000
Q2 2023 Aug 14, 2023	BUY	$2.05 - $6.1 $1.01 Million - $3 Million	492,596 New	492,596 $2.2 Million

12.9M

19.3K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $99M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.